[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598625":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":24,"centralContacts":28,"locations":33,"responsibleParty":82,"collaborators":85,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":91,"sex":97,"minAge":98,"maxAge":23,"enrollmentInfo":99,"targetDuration":23,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":115,"whyStopped":23,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"University of Pittsburgh","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Intervention Arm","Immediately gets the intervention of the implementation strategy bundle.",[12],"Behavioral: Implementation strategy bundle",{"label":14,"type":6,"description":15,"interventionNames":16},"Waitlist Control Arm","Waits for 6 months with no intervention, then gets the intervention of the implementation strategy bundle.",[12],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"BEHAVIORAL","Implementation strategy bundle","The anticipated strategy bundle will include integrated patient-, provider-, and system-level interventions to support sustainable implementation. At the patient level, this may involve education, peer support, and navigation services; at the provider level, training, decision-support tools, and workflow enhancements; and at the system level, policy changes, electronic health record integration, and organizational alignment to promote and maintain prescribing of PrEP and injection equipment.",[9,14],null,[25],{"name":26,"affiliation":5,"role":27},"Raagini Jawa, MD, MPH","PRINCIPAL_INVESTIGATOR",[29],{"name":26,"role":30,"phone":31,"phoneExt":23,"email":32},"CONTACT","(412) 232-6275","rjawa@pitt.edu",[34,52,63,72],{"facility":35,"status":23,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Latterman Family Health Center","Pittsburgh","Pennsylvania","15132","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-79.99589,40.44062,{"lat":45,"lon":44},[48],{"name":49,"role":30,"phone":50,"phoneExt":23,"email":51},"Hannah Scears","(412) 673-5504","scearshe@upmc.edu",{"facility":53,"status":23,"city":36,"state":37,"zip":54,"country":39,"countryCode":40,"cosmosGeoPoint":55,"geoPoint":57,"contacts":58},"Center for Psychiatric And Chemical Dependency Services","15213",{"type":42,"coordinates":56},[44,45],{"lat":45,"lon":44},[59],{"name":60,"role":30,"phone":61,"phoneExt":23,"email":62},"Megan Ganung","(412) 246-5910","ganungm2@upmc.edu",{"facility":64,"status":23,"city":36,"state":37,"zip":54,"country":39,"countryCode":40,"cosmosGeoPoint":65,"geoPoint":67,"contacts":68},"Internal Medicine Recovery Engagement Program",{"type":42,"coordinates":66},[44,45],{"lat":45,"lon":44},[69],{"name":70,"role":30,"phone":31,"phoneExt":23,"email":71},"Ariana Freund","freundam2@upmc.edu",{"facility":73,"status":23,"city":36,"state":37,"zip":54,"country":39,"countryCode":40,"cosmosGeoPoint":74,"geoPoint":76,"contacts":77},"UPMC Magee-Womens Hospital",{"type":42,"coordinates":75},[44,45],{"lat":45,"lon":44},[78],{"name":79,"role":30,"phone":80,"phoneExt":23,"email":81},"Ilana Hull, MD","412-530-6154","hulli@upmc.edu",{"type":27,"investigatorFullName":83,"investigatorTitle":84,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"Raagini Jawa","Assistant Professor of Medicine",[86],{"name":87,"class":88},"National Institute on Drug Abuse (NIDA)","NIH","100598625","prescribe-to-prevent-hiv-a-hybrid-trial-helping-addiction-clinics-prevent-hiv--infections-through-safer-drug-use-support-100598625",false,"NCT07073924","Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support","Prescribe to Prevent HIV (P2PH): Enhancing Clinic-based Prescribing of Harm Reduction: A Clinical Trial to Prevent HIV and Severe Injection-related Infections Among PWID","P2PH","Patients:\n\nPre-implementation interviews (N=12), pre-implementation focus groups (N=8), and post-implementation interviews (N=10)\n\nInclusion Criteria:\n\n-Adult patients with history of active injection drug use in the past 1 year from the 4 COEs\n\nExclusion Criteria:\n\n* Ages \\\u003C18\n* If history of injection drug use \\>1 year\n* Non-English speaking\n* Pending or legal action that could prohibit or interfere with participation (Ie. incarceration)\n* Residence or discharge to a treatment facility that bans the possession of drug checking supplies\n* Acute, severe psychiatric condition in need of immediate treatment.\n\nClinical Partners:\n\nPre-implementation interviews (N=12), pre-implementation focus groups (N = 24), post-implementation surveys (N = 80), and post-implementation interviews (N=10)\n\nInclusion Criteria:\n\n-Prescribing clinicians (e.g., physicians, advanced practice providers such as nurse practitioners and physician assistants), administrators, medical assistants, and nurses from the 4 COEs\n\nExclusion Criteria:\n\n* Individuals not affiliated with the 4 COEs.\n* Staff outside the specified roles (i.e., not prescribing clinicians, administrators, medical assistants, or nurses).\n* Students, trainees, or individuals not credentialed in the eligible roles.\n* Those on extended leave or not actively working during the study period.","ALL","18 Years",{"count":100,"type":101},536,"ESTIMATED","INTERVENTIONAL",[104],"NA","In the U.S., an estimated 3.6 million people who inject drugs (PWID) face a growing yet preventable health crisis, with rising cases of serious injection-related infections (SIRI), including HIV, due to limited access to two high-priority interventions: sterile injection equipment and daily oral HIV pre-exposure prophylaxis (PrEP). Outpatient clinics represent an opportune venue to implement these interventions. Yet most clinical providers in these settings do not currently provide them, contributing to a wide gap between evidence and routine practice. The Prescribe to Prevent HIV (P2PH) trial is a participatory study designed to co-develop and pilot test a set of implementation strategies to support outpatients clinics in offering sterile injection equipment and PrEP with the goal of reducing the risk of HIV and SIRI among PWID. This study is supported by the HEAL Initiative (https:\u002F\u002Fheal.nih.gov\u002F).",[107],"People Who Use Opioids\u002FPeople With Opioid Use Disorder (OUD)",[109,110,111,112,113,114],"people who use drugs","HIV","PrEP","Opioid-Related Disorders","implementation","Substance-Related Disorders","NOT_YET_RECRUITING","2026-06-06",{"date":118,"type":119},"2026-06-09","ACTUAL",{"date":121,"type":101},"2026-08-01",{"date":123,"type":101},"2028-06",{"name":5,"class":6},4]